There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
Results for performance period 4 of the Oncology Care Model just came out; what are the initial takeaways?
Practices that consistently have performed well continued to perform well. Practices that were trending in the right direction, but maybe haven’t made savings, a few of our practices have made savings, they made it over that finish line, and we’ve set that expectation that that is likely to happen given the good work that they were doing, and they’re seeing those results. And practices that haven’t performed well consistently, no surprise, didn’t get a very good report card with this reconciliation.
About half of our practices earned a PBP [performance-based payment] by this period, which is a performance period 4. That’s an increase in what we saw since performance period 3, which was about a third of our customer base earned a savings payment.
So, that was exciting news. I think overall, practices are happy with the results. I’m seeing a lot of smiling faces based on those results here, at [the Quality Cancer Care Alliance Fall 2019 Leadership Summit], which is great. But they’re a high-performing group, so they’re biased in that way, as they’re more progressive and stronger performing than some of the other practices that we work with. But good results overall, I think.
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More